Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor

被引：50

作者：

Bryce, A. ^{[3
]}

Ryan, C. J. ^{[1
,2
]}

机构：

[1] Univ Calif San Francisco, Dept Med & Urol, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[3] Mayo Clin, Dept Med, Scottsdale, AZ USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 91卷 / 01期

关键词：

RESISTANT PROSTATE-CANCER; ANTITUMOR-ACTIVITY; CYTOCHROME P450(17-ALPHA); ANTIANDROGEN WITHDRAWAL; CONCOMITANT USE; PHASE-II; IN-VITRO; CASTRATION; RECEPTOR; CYP17;

D O I：

10.1038/clpt.2011.275

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In April 2011, abiraterone acetate (AA) was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer (CRPC) after chemotherapy. The development of AA is the direct result of our increased understanding of the intricacies of the androgen receptor (AR) pathway and its natural evolution in prostate cancer cells over the course of treatment. In this paper we review the biology of the AR and how it led to the rational design of AA. We also examine the clinical development of AA, its current use, and questions to be addressed for future development.

引用

页码：101 / 108

页数：8

共 52 条

[1]

Agus DB, 2011, J CLIN ONCOL, V29

[2] Expanding Treatment Options for Metastatic Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Eisenberger, Mario A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :2055-2058

[3] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Yap, Timothy A. ;

Raynaud, Florence ;

Dowsett, Mitch ;

Settatree, Sarah ;

Barrett, Mary ;

Parker, Christopher ;

Martins, Vanessa ;

Folkerd, Elizabeth ;

Clark, Jeremy ;

Cooper, Colin S. ;

Kaye, Stan B. ;

Dearnaley, David ;

Lee, Gloria ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571

[4] Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) :E560-E561

[5] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

A'Hern, Roger ;

Parker, Christopher ;

Oommen, Nikhil Babu ;

Folkerd, Elizabeth ;

Messiou, Christina ;

Molife, L. Rhoda ;

Maier, Gal ;

Thompson, Emilda ;

Olmos, David ;

Sinha, Rajesh ;

Lee, Gloria ;

Dowsett, Mitch ;

Kaye, Stan B. ;

Dearnaley, David ;

Kheoh, Thian ;

Molina, Arturo ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3742-3748

[6] PHARMACOLOGY OF NOVEL STEROIDAL INHIBITORS OF CYTOCHROME P450(17-ALPHA) (17-ALPHA-HYDROXYLASE C17-20 LYASE) [J].

BARRIE, SE ;

POTTER, GA ;

GODDARD, PM ;

HAYNES, BP ;

DOWSETT, M ;

JARMAN, M .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1994, 50 (5-6) :267-273

[7] PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer [J].

Bismar, Tarek A. ;

Yoshimoto, Maisa ;

Vollmer, Robin T. ;

Duan, Qiuli ;

Firszt, Matthew ;

Corcos, Jacques ;

Squire, Jeremy A. .

BJU INTERNATIONAL, 2011, 107 (03) :477-485

[8] Contribution of the androgen receptor to prostate cancer predisposition and progression [J].

Buchanan, G ;

Irvine, RA ;

Coetzee, GA ;

Tilley, WD .

CANCER AND METASTASIS REVIEWS, 2001, 20 (3-4) :207-223

[9] Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer [J].

Carver, Brett S. ;

Chapinski, Caren ;

Wongvipat, John ;

Hieronymus, Haley ;

Chen, Yu ;

Chandarlapaty, Sarat ;

Arora, Vivek K. ;

Le, Carl ;

Koutcher, Jason ;

Scher, Howard ;

Scardino, Peter T. ;

Rosen, Neal ;

Sawyers, Charles L. .

CANCER CELL, 2011, 19 (05) :575-586

[10] 3- and 4-pyridylalkyl adamantanecarboxylates: Inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C-17,C-20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer [J].

Chan, FCY ;

Potter, GA ;

Barrie, SE ;

Haynes, BP ;

Rowlands, MG ;

Houghton, J ;

Jarman, M .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (17) :3319-3323

← 1 2 3 4 5 6 →